富马酸丙酚替诺福韦长期治疗慢性乙型肝炎结果:高病毒抑制率及良好的肾脏与骨骼安全性
两项3期研究5年更新结果显示,慢性乙型肝炎患者接受富马酸丙酚替诺福韦(TAF)治疗,第5年85%达到HBV DNA<29 IU/mL,无耐药发生,肾脏和骨骼安全性良好;从富马酸替诺福韦二吡呋酯(TDF)转换至TAF者相关参数有改善。
要点
- TAF治疗5年病毒抑制率高,未发现TAF或TDF耐药。
- TAF组第5年eGFR(Cockcroft-Gault)中位下降<2.5 mL/min,髋部和脊柱骨密度平均下降<1%。
- TDF转换至TAF者第5年肾脏和骨骼参数有改善。
核心结论
- 长期TAF治疗慢性乙型肝炎可获得高病毒抑制率、无耐药发生,并具有良好的肾脏和骨骼安全性。
研究设计与样本
- 两项3期双盲随机研究(TAF 25 mg vs TDF 300 mg,2:1)后开放标签TAF延伸至8年,共纳入1298例随机治疗患者。
主要发现
- 第5年HBV DNA<29 IU/mL(缺失=失败)率:TAF组85%,TDF→TAF3y组83%,TDF→TAF2y组90%。
- 无患者发生TAF或TDF耐药。
- TAF组第5年eGFR(Cockcroft-Gault)中位下降<2.5 mL/min,髋部和脊柱骨密度平均下降<1%。
- TDF→TAF组在转换至开放标签TAF后第5年肾脏和骨骼参数有改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior renal and bone safety. We report updated results through 5 years. METHODS: Patients with HBeAg-negative or HBeAg-positive chronic hepatitis B infection with or without compensated cirrhosis were randomized (2:1) to TAF 25 mg or TDF 300 mg once daily in double-blind (DB) fashion for up to 3 years, followed by open-label (OL) TAF up to 8 years. Efficacy (antiviral, biochemical, and serologic), resistance (deep sequencing of polymerase/reverse transcriptase and phenotyping), and safety, including renal and bone parameters, were evaluated by pooled analyses. RESULTS: Of 1,298 randomized and treated patients, 866 receiving TAF (DB and OL) and 432 receiving TDF with rollover to OL TAF at year 2 (n = 180; TDF→TAF3y) or year 3 (n = 202; TDF→TAF2y) were included. Fifty (4%) TDF patients who discontinued during DB were excluded. At year 5, 85%, 83%, and 90% achieved HBV DNA <29 IU/mL (missing = failure) in the TAF, TDF→TAF3y, and TDF→TAF2y groups, respectively; no patient developed TAF or TDF resistance. Median estimated glomerular filtration rate (by using Cockcroft-Gault) declined <2.5 mL/min, and mean declines of <1% in hip and spine bone mineral density were seen at year 5 in the TAF group; patients in the TDF→TAF groups had improvements in these parameters at year 5 after switching to OL TAF. DISCUSSION: Long-term TAF treatment resulted in high rates of viral suppression, no resistance, and favorable renal and bone safety.
引用
- Chan HLY, Buti M, Lim YS, et al. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. Am J Gastroenterol. 2023. PMID: 37561058. doi:10.14309/ajg.0000000000002468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。